Education
About Us
Working with TipRanks
Follow Us
Gentian Diagnostics ASA (DE:6FK)
FRANKFURT:6FK
6FK Stock Chart & Stats
Day’s Range― - ―
52-Week Range€3.18 - €5.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€75.88M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)15.32M
Price to Earnings (P/E)17.8
Beta0.63
Next Earnings
Jul 10, 2025EPS EstimateN/A
Last Dividend Ex-Date
May 07, 2025Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding15,422,350
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Gentian Diagnostics ASA News
PremiumCompany Announcements
Norda ASA Increases Stake in Gentian Diagnostics
PremiumCompany Announcements
Gentian Diagnostics ASA to Present Q1 2025 Financial Results
PremiumCompany Announcements
Gentian Diagnostics ASA Schedules 2025 Annual General Meeting
PremiumCompany Announcements
Gentian Board Member Acquires Shares Amid Regulatory Compliance
PremiumCompany Announcements
Gentian Diagnostics ASA Strengthens Leadership for Global Growth
PremiumCompany Announcements
Gentian Diagnostics Releases 2024 Annual ReportPremiumCompany Announcements
Gentian Diagnostics Releases 2024 Annual Report---
6FK FAQ
What was Gentian Diagnostics ASA’s price range in the past 12 months?
Gentian Diagnostics ASA lowest stock price was €3.18 and its highest was €5.05 in the past 12 months.
What is Gentian Diagnostics ASA’s market cap?
Gentian Diagnostics ASA’s market cap is €75.88M.
When is Gentian Diagnostics ASA’s upcoming earnings report date?
Gentian Diagnostics ASA’s upcoming earnings report date is Jul 10, 2025 which is in 50 days.
How were Gentian Diagnostics ASA’s earnings last quarter?
Gentian Diagnostics ASA released its earnings results on May 07, 2025. The company reported €0.043 earnings per share for the quarter, beating the consensus estimate of N/A by €0.043.
Is Gentian Diagnostics ASA overvalued?
According to Wall Street analysts Gentian Diagnostics ASA’s price is currently Overvalued.
Does Gentian Diagnostics ASA pay dividends?
Gentian Diagnostics ASA pays a Notavailable dividend of €0.035 which represents an annual dividend yield of N/A. See more information on Gentian Diagnostics ASA dividends here
What is Gentian Diagnostics ASA’s EPS estimate?
Gentian Diagnostics ASA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gentian Diagnostics ASA have?
Gentian Diagnostics ASA has 15,422,350 shares outstanding.
What happened to Gentian Diagnostics ASA’s price movement after its last earnings report?
Gentian Diagnostics ASA reported an EPS of €0.043 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.951%.
Which hedge fund is a major shareholder of Gentian Diagnostics ASA?
Currently, no hedge funds are holding shares in DE:6FK
---
Company Description
Gentian Diagnostics ASA
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. The company was incorporated in 2001 and is headquartered in Moss, Norway.
---
Technical Analysis
---